Investigators at the MD Anderson Cancer Center (MDACC), Fred Hutchinson Cancer Center (FHCC), Arizona State University (ASU), University of Toronto, and the Massachusetts General Hospital (MGH) have measured 26 different biomarkers and compared 5 different assays for anti-TP53 AAb using serum samples from patients with early and late stage ovarian cancer, benign pelvic masses and healthy controls. This evidence concerns the gene TP53 and ovarian carcinoma.